Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improvement in sinonasal quality-of-life indicators for pediatric patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.

International forum of allergy & rhinology - 1 Jan 2023

Castellanos Carlos X, Osterbauer Beth, Hasday Steven, Keens Thomas G, Koempel Jeffrey, Ference Elisabeth H

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Child
Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Combinations

Share to Mutation

Share to Quality of Life

Source

Identifiers

PMID: 35643960
DOI: 10.1002/alr.23036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improvement in sinonasal quality-of-life indicators for pediatric patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.PMID 35643960Read ↗

Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?Semantic proximity Read ↗

Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutationSemantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.Semantic proximity Read ↗

Real Life With Tezacaftor and Ivacaftor in Adult Patients With Cystic Fibrosis: Spanish Multicenter Study.Semantic proximity Read ↗

Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.Semantic proximity Read ↗

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort.Semantic proximity Read ↗

Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.Semantic proximity Read ↗

Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.Semantic proximity Read ↗

Elexacaftor-tezacaftor-ivacaftor increases airway nitric oxide in children with cystic fibrosis.Semantic proximity Read ↗

Tezacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.